Mostrando 1 - 2 Resultados de 2 Para Buscar 'International Breast Cancer Study Group', tiempo de consulta: 0.30s Limitar resultados
1
artículo
Treatment Efficacy, Adherence, and Quality of Life Among Women Younger Than 35 Years in the International Breast Cancer Study Group TEXT and SOFT Adjuvant Endocrine Therapy Trials
Publicado por
Saha, P, Regan, MM, Pagani, O, Francis, PA, Walley, BA, Ribi, K, Bernhard, J, Luo, W, Gómez, HL, Burstein, HJ, Parmar, V, Torres, R, Stewart, J, Bellet, M, Perelló, A, Dane, F, Moreira, A, Vorobiof, D, Nottage, M, Price, KN, Coates, AS, Goldhirsch, A, Gelber, RD, Colleoni, M, Fleming, GF, SOFT TEXT Investigators, International Breast Cancer Study Group
Publicado 2017 Enlace
Purpose To describe benefits and toxicities of adjuvant endocrine therapies in women younger than 35 years with breast cancer (n = 582) enrolled in the Suppression of Ovarian Function Trial (SOFT) and Tamoxifen and Exemestane Trial (TEXT). Methods In SOFT, women still premenopausal after surgery with or without chemotherapy were randomly assigned to tamoxifen alone, tamoxifen plus ovarian function suppression (OFS), or exemestane plus OFS. In TEXT, all received OFS with or without concomitant chemotherapy and were randomly assigned to exemestane plus OFS or tamoxifen plus OFS. We summarize treatment efficacy, quality of life, and adherence of the cohort of women younger than 35 years in SOFT and TEXT, alongside data from the cohort of older premenopausal women. Results For 240 human epidermal growth factor receptor 2-negative patients younger than 35 years enrolled in SOFT after receivin...
Agregar a favoritos
Guardado en:
2
artículo
Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer
Publicado por
Francis, PA, Pagani, O, Fleming, GF, Walley, BA, Colleoni, M, Láng, I, Gómez, HL, Tondini, C, Ciruelos, E, Burstein, HJ, Bonnefoi, HR, Bellet, M, Martino, S, Geyer, CE, Goetz, MP, Stearns, V, Pinotti, G, Puglisi, F, Spazzapan, S, Climent, MA, Pavesi, L, Ruhstaller, T, Davidson, NE, Coleman, R, Debled, M, Buchholz, S, Ingle, JN, Winer, EP, Maibach, R, Rabaglio-Poretti, M, Ruepp, B, Di Leo, A, Coates, AS, Gelber, RD, Goldhirsch, A, Regan, MM, SOFT and TEXT Investigators and the International Breast Cancer Study Group.
Publicado 2018 Enlace
Background: In the Suppression of Ovarian Function Trial (SOFT) and the Tamoxifen and Exemestane Trial (TEXT), the 5-year rates of recurrence of breast cancer were significantly lower among premenopausal women who received the aromatase inhibitor exemestane plus ovarian suppression than among those who received tamoxifen plus ovarian suppression. The addition of ovarian suppression to tamoxifen did not result in significantly lower recurrence rates than those with tamoxifen alone. Here, we report the updated results from the two trials. Methods: Premenopausal women were randomly assigned to receive 5 years of tamoxifen, tamoxifen plus ovarian suppression, or exemestane plus ovarian suppression in SOFT and to receive tamoxifen plus ovarian suppression or exemestane plus ovarian suppression in TEXT. Randomization was stratified according to the receipt of chemotherapy. Results: In SOFT, th...
Agregar a favoritos
Guardado en: